% | $
Quotes you view appear here for quick access.

Titan Medical Inc. Message Board

cuin2 9 posts  |  Last Activity: Apr 9, 2016 11:02 PM Member since: Jan 24, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Great news....New CMO for ECIG listed on LinkedIn - Monsell Darville, started in April.
    Impressive background as VP/Marketing Director for Bacardi for 10 years and SVP Managing Partner for the Legendary Hatfield & McCoy Family Brands/Gas Monkey Tequila most recently.

    Sentiment: Strong Buy

  • Electronic Cigarettes International Group, Ltd. (The “Company”) (OTCBB: ECIG), a global marketer and distributor of electronic cigarettes and vapor products whose brands include FIN, Vapestick, Victory, VIP, and others, today announced the appointment of Hein & Associates LLP as its new independent auditor, which was made effective on April 5, 2016, with approval from the Board of Directors.

    Hein & Associates replaces Rehmann Robson LLC. The decision to change auditors was not the result of any disagreement between the Company and Rehmann Robson on any matter of accounting principle or practice, financial statement disclosures or auditing scope or procedure.

    As part of ECIG’s transformation, which includes the relocation of its headquarters to Golden, Colorado, the Company made the decision to change auditors. Hein & Associates is an independent registered public accounting firm formed in 1977 and headquartered in Denver, Colorado. The firm also has offices in Houston, Texas, Dallas, Texas and Orange County, California. Hein & Associates is the auditor of record for more than 45 SEC registrants.

    Sentiment: Strong Buy

  • Robotic surgery updates: Hansen reveals $15.3M accounting error; Titan prices equity offering
    April 1, 2016 | By Varun Saxena

    Robotic Surgery aspirants Titan Medical and Hansen Medical are moving in opposite directions, as the battle to become the chief competitor to market leader Intuitive Surgical ($ISRG) heats up.

    Mountain View, CA's Hansen Medical announced a $15.3 million accounting error. The company had a loss of $48.9 million during Q2, not the previously stated $33.5 million. The news will complicate its search for an acquirer. The company announced it was exploring "strategic alternatives" in January.

    Meanwhile, Toronto's Titan announced that it has priced its equity offering at CA$1.00 ($0.76) per unit. Each unit consists of one common share and one warrant, which gives investors the right to acquire an additional common share for CA$1.20 ($0.91) over a period of 5 years following the closing of the offering.

    [Webinar] Leveraging Forecasting Models to Optimize Clinical Trial Supply Management

    Explore how to drive excellence within the clinical supply forecasting process and apply forecasting models to identify potential supply-related issues before they negatively impact your study. Reserve Your Spot Today!
    Sign up for our FREE newsletter for more news like this sent to your inbox!
    The company recently unveiled its single-arm Sport robotic surgery system to investors, with a goal of FDA clearance and a U.S. launch by mid-2017. In December it announced it is licensing know-how and technology from the Mayo Clinic related to use of the device in colorectal surgery.

    Others are in the race to develop the second successful robotic surgery device, following the success of Intuitive's da Vinci robot. The company received its first clearance back in 2001, the FDA's database shows, but is only now starting to face significant competition, due to initial doubts that paradigm-shifting,

    Sentiment: Strong Buy

  • Reply to


    by cuin2 Mar 21, 2016 8:11 PM
    cuin2 cuin2 Mar 21, 2016 8:48 PM Flag

    Why would you. It want to know? Are you an investor in Titan? Or short?

  • Any guesses who I saw outside the SAGES Exhibit Hall at 925am Friday with Mr Hargrove and walked in together to Titans Booth???

    I recognized these two gentleman instantly. They spent a solid amount of time at Titans booth talking to management and observing a SPORT demonstration. I also happened to be at Transenterix's booth when they walked by and said "hey guys, I just wanted to stop by and say hi." Then quickly moved on.

    I found all this fascinating. Not suggesting anything other than a coincidence, of course!

    Copied from Titan Medical IHUB Message Board:

    To find out who it was, go to the Titan Medical FaceBook Page or the Titan Medical IHUB Message Board.

    Sentiment: Strong Buy

  • Reply to

    Three day rule after a significant up side

    by mike.dayton Mar 11, 2016 1:31 PM
    cuin2 cuin2 Mar 20, 2016 5:57 PM Flag


    The problem with Surgibot is that it is not truly robotic (like da Vinci). They took their SPIDER System and modified into a larger system to "look" robotic and that's why TRXC bought the Italian company and ALF-X. But ALF-X is far too big by most accounts. Plus the cost of trying to get two platforms assimilated into the market will be outrageous IMO.

    These new entrants into this sector/catergory are definitely risky. Most likely ISRG will sue all new comers. But my view has been Titan has the best overall chance right now with SPORT. There is a Titan Facebook page dedicated to the recent SAGE's Conference with great photos, videos and comments from surgeons and other Titan shareholders who attended. You should check it out.

    Until something better comes along, this is where I have parked my money. Best of luck to you.

    Sentiment: Strong Buy

  • Reply to

    Three day rule after a significant up side

    by mike.dayton Mar 11, 2016 1:31 PM
    cuin2 cuin2 Mar 18, 2016 7:53 AM Flag

    Let me know when we have a "significant up side".

  • 1)
    Sport intrigues me. I am a gyn oncologist and I use the DaVinci regularly. Sport has shown me it is everything it was advertised to be. But I am not sure that it threatens ISRG as much as it does traditional laparoscopy. Certainly it will challenge ISRG 's market to an extent, but if the price point is right, then traditional laparoscopy is gone. That is the way I see it. And that is a bigger deal then directly competing with ISRG. The traditional laparoscopic companies should be worried.
    2) A capital ISRG 2 years ago told me about TITXF. At that time he was concerned about future competition from TITXF. Currently I know many of the reps are concerned about their domination of the market being impacted by SPORT. I know little about stocks but I've been a physician for 15 years and as a gynecologist I use robotics weekly. Currently nothing besides SPORT will be ready to compete with TITXF. Those videos from SAGES show a great product from my standpoint. As hospital admins are always looking for the "cheaper" product for their OR, SPORT will be the easy choice. I don't need to see the Surgibot in person at SAGES to tell you that it will not be in many ORs in the future. It's clear from watching their online videos. As a surgeon robotic surgery is where laparoscopic (most) surgery is going. There is now a clear competitor to TITXF. I'm not worried about the FDA approval. I am a little concerned about ISRG trying to block it's going to market because of some patent violation. Any attorneys out there that think this might be an issue?

    Copied from Titan Medical IHUB message board

    Sentiment: Strong Buy

  • Reply to


    by precisionhome Mar 1, 2016 8:14 PM
    cuin2 cuin2 Mar 1, 2016 10:21 PM Flag

    Long investors will be paid handsomely this year. Dan O'Neill is not fooling around here.

    Sentiment: Strong Buy

0.71-0.01(-2.07%)Apr 29 3:52 PMEDT